Referenzen Moderne orale Substanzen A-Z

 
  1. Swissmedic Arzneimittelinformation 
  2. Pleyer L, Greil R. Arzneimittelprofil Dasatinib. Medizin Medien Austria. November 2007 
  3. Li J, Uhao M, He P et al. Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes. Clin Canc Res 2007; 13: 3731-3737  
  4. Eickhoff C, Schulz M. Imatinib, ein Tyrosinkinase-Inhibitor. Pharmazeutische Zeitschrift online 2003. Ausgabe 19  
  5. Rumpold H, Gastl G, Wolf D. Arzneimittelprofil Nilotinib. Medizin Medien Austria. März 2008 
  6. Bhojani N et al. Toxicities Associated with the Administration of Sorafenib, Sunitinib and Temsirolimus and Their Management. 2008; 53: 917-930 
  7. Greil R, Micksche M. Arzneimittelprofil Sorafenib. Medizin Medien Austria. Dezember 2006 
  8. Schmidinger M, Loidl W. Arzneimittelprofil Sunitinib. Medizin Medien Austria. April 2007 
  9. Übersetzung der australischen Produktinformation zu Thalidomide Pharmion 50 mg Hartkapseln. Version 1, 23. August 2004
  10. Europäische Fachinformation Thalidomide: http://www.emea.europa.eu/humandocs/Humans/EPAR/thalidomidecelgene/thalidomidecelgene.htm 
  11. Marty M, Fumoleau P, Adenis A et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12: 1643-1649, 2001 
  12. Nguyen L, Tranchand B, Puozzo C et al. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trial. Clin Pharmacol. 53, 459-468. 
  13. Yeh ETH, et al. Cardiovascular Complications of Cancer Therapy Incidence, Pathogenesis, Diagnosis, and Management J Am Coll Cardiol 2009; 53: 2231–47 
  14. Van Cutsem E, Hoff PM, Blum JL, Abt M, Osterwalder B. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002;13:484 –5. 
  15. Kosmas C, Kallistratos MS, Kopterides P, et al. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol 2008; 134: 75– 82. 
  16. Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer 2005; 41: 1542– 6. 
  17. Saif MW, Tomita M, Ledbetter L, Diasio RB. Capecitabine-related cardiotoxicity: recognition and management. J Support Oncol 2008; 6 :41– 8. 
  18. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005; 27: 23–44. 
  19. Cardinale D, Colombo A, Colombo N. Acute coronary syndrome induced by oral capecitabine. Can J Cardiol 2006; 22: 251–3. 
  20. Singer M. Cardiotoxicity and capecitabine: a case report. Clin J Oncol Nurs 2003; 7: 72–5. 
  21. Bertolini A, Flumano M, Fusco O, et al. Acute cardiotoxicity during capecitabine treatment: a case report [in Italian]. Tumori 2001; 87: 200–6. 
  22. Schnetzler B, Popova N, Collao Lamb C, Sappino AP. Coronary spasm induced by capecitabine. Ann Oncol 2001; 12: 723– 4. 
  23. Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002; 13: 797– 801. 
  24. Arbea L, Coma-Canella I, Martinez-Monge R, Garcia-Foncillas J. A case of capecitabine-induced coronary microspasm in a patient with rectal cancer. World J Gastroenterol 2007; 13: 2135–7. 
  25. Sestito A, Sgueglia GA, Pozzo C, et al. Coronary artery spasm induced by capecitabine. J Cardiovasc Med (Hagerstown) 2006; 7: 136–8. 
  26. Papadopoulos CA, Wilson H. Capecitabine-associated coronary vasospasm: a case report. Emerg Med J 2008; 25: 307–9. 
  27. Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review.
  28. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 1994 May 28;343(8909):1318-21.
  29. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003 Nov;18(11):937-47.
  30. Diesing D, Friedrich M, von Otte S. Nebenwirkungen der endokrinen Therapie beim Mammakarzinom. Gynäkologische Endokrinologie 2005 (3):91-96.
  31. Vandewiele B, Vandecasteele SJ, Vanwalleghem L, De Vriese AS. Diffuse alveolar hemorrhage induced by everolimus. Chest. 2010 Feb;137(2):456-9.
  32. Aparicio G, Calvo MB, Medina V, Fernandez O, Jimenez P, Lema M, et al. Comprehensive lung injury pathology induced by mTOR inhibitors. Clin Transl Oncol. 2009 Aug;11(8):499-510.
  33. Otton J, Hayward CS, Keogh AM, Glanville AR, Macdonald PS. Everolimus-associated pneumonitis in 3 heart transplant recipients. J Heart Lung Transplant. 2009 Jan;28(1):104-6.
  34. Rodriguez-Moreno A, Ridao N, Garcia-Ledesma P, Calvo N, Perez-Flores I, Marques M, et al. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center. Transplant Proc. 2009 Jul-Aug;41(6):2163-5.
  35. Exposito V, Vasquez de Prada JA, Gomez-Roman JJ, Gonzalez-Vilchez F, Llano-Cardenal M, Garcia-Camarero T, et al. Everolimus-related pulmonary toxicity in heart transplant recipients. Journal of Heart and Lung Transplantation. 2008;27(7):797-800.
  36. David S, Kumpers P, Shin H, Haller H, Fliser D. Everolimus-associated interstitial pneumonitis in apatient with a heart transplant. Nephrology Dialysis Transplantation 2007; 22: 3363-3364.
  37. Tyverb EPAR Procuct Information 
  38. Tykerb (Lapatinib) U.S. Prescribing Information
  39. Yeh ETH, Bickford CL. Cardiovascular Complications of Cancer Therapy:Incidence, Pathogenesis, Diagnosis, and Management. J Am Coll Cardiol 2009;53:2231–47.
  40. Mellor HR, Bell AR, Valentin J-P et al. Cardiotoxicity associated with targeting kinase pathways in cancer. Toxicol. Sci. (2011) 120 (1): 14-32.
  41. Je, YMS et al.: Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. The Lancet Oncology 2009, 10(10):967-974
  42. Hamnvik OP, Larsen PR, Marqusee E.
    J Natl Cancer Inst. 2011 Nov 2;103(21):1572-87. Epub 2011 Oct 18 
  43. Zelboraf Drug Approval Package, Medical Review Nov 30, 2011
  44. Torben K. Becker; Sai-Ching J. Yeung. Drug-induced QT interval prolongation in cancer Patients. Oncol Rev 2010
  45. Langmuir P B, Yver A. Vandetanib for the Treatment of Thyroid Cancer. Clinical Pharmacology & Therapeutics 91, 71-80 doi:10.1038/clpt.2011.272
  46. Zelboraf Full Prescribing Information. Reference ID 3001518
  47. Langmuir P B, Yver A. Vandetanib for the Treatment of Thyroid Cancer. Clinical Pharmacology & Therapeutics 91, 71-80 doi:10.1038/clpt.2011.272
  48. Demetri GD et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381 (9863): 295-302
  49. Grothey A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: (9863): 303-312
  50. L. Albiges, F. Chamming’s, B. Duclos et al. Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Annals of Oncology. 2012; 00: 1-11 

Interaktionen

  1. Arzneimittelkompendium der Schweiz 
  2. Kämmerer W. Klinisch relevante pharmakokinetische Interaktionen von und mit Zytostatika. Arzneimitteltherapie 2008; 26. Jahrgang, Heft 2: 51-61 
  3. Pleyer L, Greil R. Arzneimittelprofil Dasatinib. Medizin Medien Austria. November 2007 
  4. Li J, Uhao M, He P et al. Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes. Clin Canc Res 2007; 13: 3731-3737  
  5. Eickhoff C, Schulz M. Imatinib, ein Tyrosinkinase-Inhibitor. Pharmazeutische Zeitschrift online 2003. Ausgabe 19 
  6. Drucker BJ, Sawyers CL, Capdeville R et al. Chronic myeloid leukemia. Hematology 2001: 87-112 
  7. Rumpold H, Gastl G, Wolf D. Arzneimittelprofil Nilotinib. Medizin Medien Austria. März 2008 
  8. Greil R, Micksche M. Arzneimittelprofil Sorafenib. Medizin Medien Austria. Dezember 2006 
  9. Schmidinger M, Loidl W. Arzneimittelprofil Sunitinib. Medizin Medien Austria. April 2007 
  10. Übersetzung der „Product Information” (Produktinformation) zu Thalidomide Pharmion 50 mg Hartkapseln, Version 1, 23. August 2004
  11. Thalomid (thalidomide) Capsules. Revised Package Insert, 15 July 1998
  12. Fattinger K, Roos M, Vergeres P et al. Epidemiology of drug exposure and adverse drug reaction in two Swiss departments of internal medicine. Br J Clin Pharmacol 2000; 499: 158-167 
  13. Zoppi M, Braunschweig S, Kuenzi UP et al. Incidence of lethal adverse drug reactions in the comprehensive hospital drug monitoring, a 20-year survey, 1974-1993, based on the data of Berne/St. Gallen. Eur J Clin Pharmacol 2000; 56: 427-430 
  14. Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol 2004; 5: 489-496 
  15. Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: Why are they important and can they be minmized? Crit Rev Oncol Hematol 2005; 55: 117-142 
  16. McLeod HL. Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol 1998; 45: 539-544 
  17. Lam MSH, Ignoffo RJ. A guide to clinically relevant drug interactions in oncology. J Oncol Pharm Practice 2003; 9: 45-85 
  18. Kämmerer W. Klinisch relevante pharmakokinetische Interaktionen von und mit Zytostatika. Arzneimitteltherapie 2008; 26. Jahrgang, Heft 2: 51-61 
  19. Benet LZ, Hoener BA. Changes in plasma protein bindings have little clinical relevance. Clin Pharmacol Ther 2002; 71: 115-121 
  20. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450-2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005: 56-63 
  21. Zagermann-Muncke P. Wenn Arzneistoffe die Transportproteine beeinflussen. PZ Pharmazeutische Zeitung online 2006; 50 
  22. Hoffmeyer S, Burk O, von Richter O et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000; 97: 3473-3478 
  23. Marchetti S, Mazzanti R, Beijnen J H et al. Concise review: Clinical relevance of drug-drug and herb-drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). The Oncologist 2007; 12: 927-941 
  24. Marty M, Fumoleau P, Adenis A et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients with solid tumors. Ann Oncol 12: 1643-1649, 2001 
  25. Nguyen L, Tranchand B, Puozzo C et al. Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trial. Clin Pharmacol. 53, 459-468. 

Unerwünschte Wirkungen und Behandlungsvorschläge

  1. Bhojani N et al. Toxicities Associated with the Administration of Sorafenib, Sunitinib and Temsirolimus and Their Management. 2008; 53: 917-930 
  2. Wood LS. Managing the side effects of sorafenib and sunitinib. Community Oncology, Sept. 2006; 3: 558-562 
  3. Grünwald V, Heinzer H, Fiedler W. Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie 2007; 30: 519-524 
  4. Négrier S, Ravaud A. Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. Eur J Canc 2007; Supp 5. No. 7: 12-19 
  5. Kollmannsberger C, Soulieres D, Wong R et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Ass J 2007; 1: 41-54 
  6. Cancer-Related Fatigue. NCCN Practice Guidelines in Oncology. V. 1. 2008 
  7. Wilson KG, Chochinov HM, Skirko MG et al. Depression and anxiety disorders in palliative cancer care. J Pain Symptom Manage 2007; 33: 118-129 
  8. NCCN Practice Guidelines in Oncology 
  9. Horowitz JR, Rivard A, van der Zee R et al. Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium. Arterioscler Thromb Vasc Biol 1997; 17: 2793-2800 
  10. Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 2006; 24: 1329-1331 
  11. Link H. Anämie bei Krebs. Diagnostik, Therapie, Transfusionen, Erythropoese stimulierende Agentien, Eisensubstitution. Onkologe 2009; 15: 129-141 
  12. Auerbach M, Silberstein PS, Webb T et al. Darbepoetin alfa (da) 500 mcg or 300 mcg once every three weeks (q3w) with or without iron in patients (pts) with chemotherapy-induced anemia. Ann Oncol 2008; Volume 19, Supplement 8 
  13. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22: 1301-1307 
  14. Bastit L, Vandebroek A, Altintas S et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008; 26: 1611-1618 
  15. Hedenus M, Birgegard G, Nasman P et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 2007; 21: 627-632 
  16. Henry DH, Dahl NV, Auerbach M et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007; 12: 231-242 
  17. Pedrazzoli P, Farris A, Del Prete S et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alfa. J Clin Oncol 2008; 26: 1619-1625 
  18. Schmidinger M, Loidl W. Arzneimittelprofil Sunitinib. Medizin Medien Austria. April 2007 
  19. Benson AB, Ajani JA, Catalano RB et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22: 2918-26 
  20. Schmidinger M. Oncology Update Symposium: Krebsmanagement in der modernen Onkologie. Zürich 11. September 2008
  21. Ginger (Zingiber officinale Roscoe) 
  22. Festa RD, Kearney P, Rosenbau IR et al. Nutrition Issues 
  23. http://www.palliativ-luzern.ch/de/04_ratgeber/empfehlungen-fuer-fachpersonen 
  24. Beglinger C, Bauerfeind F, Bollier AM et al. Obstipation: Wichtige Triagefunktion der Apotheker. PharmaJournal 2008; 12/6: 5-10
  25. OFSP (Office fédéral de la santé publique) 
  26. Robert C, Soria JC, Spatu A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500 
  27. Staehler M, Haseke N, Schöppler G et al. Antiangiogenetische Therapie beim Nierenzellkarzinom. Management der Nebenwirkungen. Urologe 2006; 45: 1333-1344 
  28. American Society of Clinical Oncology (ASCO) 
  29. Kamba T and McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. British Journal of Cancer 2007; 96(12):1788-1795 
  30. Caravatti M, Kleinert B, Michel BA. Konservative Therapie lumbaler Rückenschmerzen. Schweiz Med Forum 2001; 9: 209-212 
  31. Honkaniemi J, Kahara V, Dastidar P, Latvala M, Hietaharju A, Salonen T, Keskinen L, Ollikainen J, Vahamaki L, Kellokumpu-Lehtinen P, Frey H. Reversible posterior leukoencephalopathy after combination chemotherapy. Neuroradiology 2000; 42: 895-899 
  32. Sanchez-Carpintero R, Narbona J, Lopez de Mesa R, Arbizu J, Sierrasesumaga L. Transient posterior encephalopathy induced by chemotherapy in children. Pediatr Neurol 2001; 24: 145-148 
  33. Briganti C, Caulo M, Notturno F, Tartaro A, Uncini A. Asymptomatic spinal cord involvement in posterior reversible encephalopathy syndrome. Neurology. 2009 Nov 3;73(18):1507-8. No abstract available.
  34. Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002 Jun-Jul;23(6):1038-48.
  35. Arbeitsgruppe für Herzinsuffizienz der Schweizerischen Gesellschaft für Kardiologie. Empfehlungen zur Diagnose und Behandlung der chronischen Herzinsuffizienz . SAEZ 2002;83(24):1233-1242.
  36. Zbinden S, Bühlmann M, Aebi S, Suter T. Kardiovaskuläre Nebenwirkungen der modernen Medikamentösen Krebstherapie. Schweiz Med Forum 2010;10(8):143-147 
  37. Coombes, R.C., et al., A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med, 2004. 350(11): p. 1081-92.
  38. Goss, P.E., et al., A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med, 2003. 349(19): p. 1793-802.
  39. Buzdar, A., et al., Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol, 2001. 19(14): p. 3357-66.
  40. Richette, P., M. Corvol, and T. Bardin, Estrogens, cartilage, and osteoarthritis. Joint Bone Spine, 2003. 70(4): p. 257-62.
  41. Burstein, H.J., Aromatase inhibitor-associated arthralgia syndrome. Breast, 2007. 16(3): p. 223-34.
  42. Cuzick, J., et al., Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol, 2008. 9(12): p. 1143-8.
  43. Thorne, C., Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol, 2007. 14 Suppl 1: p. S11-9.
  44. Presant, C.A., et al., Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer, 2007. 7(10): p. 775-8.
  45. Mao, J.J., et al., Feasibility trial of electroacupuncture for aromatase inhibitor--related arthralgia in breast cancer survivors. Integr Cancer Ther, 2009. 8(2): p. 123-9.
  46. Khan, Q.J., et al., Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat, 2010. 119(1): p. 111-8.
  47. Khan, Q.J., A.P. O'Dea, and P. Sharma, Musculoskeletal adverse events associated with adjuvant aromatase inhibitors. J Oncol, 2010. 2010.
  48. Monnier, A., Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer. Ann Oncol, 2007. 18 Suppl 8: p. viii36-44.
  49. Hong, S., et al., The expanding use of third-generation aromatase inhibitors: what the general internist needs to know. J Gen Intern Med, 2009. 24 Suppl 2: p. S383-8.
  50. Hickey, M., et al., Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol, 2008. 19(10): p. 1669-80.
  51. Monnier, A., Clinical management of adverse events in adjuvant therapy for hormone-responsive early breast cancer. Ann Oncol, 2007. 18 Suppl 8: p. viii36-44.
  52. Whiteman, M.K., et al., Smoking, body mass, and hot flashes in midlife women. Obstet Gynecol, 2003. 101(2): p. 264-72.
  53. Thurston, R.C., et al., Physical activity and risk of vasomotor symptoms in women with and without a history of depression: results from the Harvard Study of Moods and Cycles. Menopause, 2006. 13(4): p. 553-60.
  54. Milne, H.M., et al., Association between physical activity and quality of life among Western Australian breast cancer survivors. Psychooncology, 2007. 16(12): p. 1059-68.
  55. Barton, D.L., et al., Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol, 1998. 16(2): p. 495-500.
  56. Hirata, J.D., et al., Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril, 1997. 68(6): p. 981-6.
  57. Jacobson, J.S., et al., Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol, 2001. 19(10): p. 2739-45.
  58. Penotti, M., et al., Effect of soy-derived isoflavones on hot flushes, endometrial thickness, and the pulsatility index of the uterine and cerebral arteries. Fertil Steril, 2003. 79(5): p. 1112-7.
  59. Baber, R.J., et al., Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric, 1999. 2(2): p. 85-92.
  60. Irvin, J.H., et al., The effects of relaxation response training on menopausal symptoms. J Psychosom Obstet Gynaecol, 1996. 17(4): p. 202-7.
  61. Elkins, G., et al., Pilot evaluation of hypnosis for the treatment of hot flashes in breast cancer survivors. Psychooncology, 2007. 16(5): p. 487-92.
  62. Mom, C.H., et al., Hot flushes in breast cancer patients. Crit Rev Oncol Hematol, 2006. 57(1): p. 63-77.
  63. Nelson, H.D., et al., Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA, 2006. 295(17): p. 2057-71.
  64. Goldberg, R.M., et al., Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol, 1994. 12(1): p. 155-8.
  65. World Health Organisation. Cancer Pain Relief WHO Publishing Geneve, 1. 1986.
  66. World Health Organisation. Cancer Pain Relief WHO Publishing Geneve, 2. 1996.
  67. World Health Organisation. Cancer pain release appraising the WHO Analgesic Ladder on its 20th anniversary Geneve, WHO 2006.
  68. Handlungsleitlinie Tumorschmerzen aus Empfehlungen zur Therapie von Tumorschmerzen (3. Auflage) Arzneimittelkommission der deutschen Ärzteschaft, Arzneiverordnung in der Praxis, Band 34, Sonderheft 1, Januar 2007.
  69. Piribauer M, Stevens S, Kloke M. ASO-Fortbildung: Neue Aspekte in der medikamentösen Schmerztherapie. Im Focus Onkologie 2006; 11: 61-65. 
  70. Ripamonti C I, Santini D, Maranzano E et al. Management of cancer pain: ESMO Clinical Practice Guidelines. Annals of Oncology 23 (Supplement 7): vii139–vii154. 
  71. Use of Opioid Analgesics in the Treatment of Cancer Pain. Evidence-based recommendations from the EAPC. Feb 2012: web version of Lancet Oncol 2012; 13: e58-e68.
  72. Dougherty L. Scalp cooling to prevent hair loss in chemotherapy. Prof. Nurse 1996; 11(8): 507–509.
  73. Lenaerts E, Meyen M, Maes T et al. Scalp cooling in the prevention of anthracycline-induced alopecia. Eur. J. Cancer 2001; 37(Suppl. 6): 360.
  74. Tierney A, Taylor J. Chemotherapy-induced hair loss. Nurs Stand 1991; 5(38): 29–31.
  75. McGarvey EL, Baum LD, Pinkerton RC et al. Psychological sequelae and alopecia among women with cancer. Cancer Pract 2001; 9(6):283-289.
  76. Munstedt K, Manthey N, Sachsse S et al. Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer 1997; 5(2): 139-43.
  77. Kath R. Nebenwirkungen von Zytostatika an Schleimhäuten, Haut und Hautanhangsgebilden: Alopezie. www.onkodin.de. Letzte Änderung: 25.01.2006
  78. Schnipper LE, Meropol NJ, Brock DW. Value and cancer care: toward an equitable future. Clin. Cancer Res. 2010; 16, 6004–6008.
  79. Van Doorn R, Kirtschig G, Scheffer E et al. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor. Br J Dermatol 2002; 147: 598–601.
  80. Graves JE, Jones BF, Lind AC et al. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J Am Acad Dermatol 2006; 55: 349–353.
  81. Burtness B, Anadkat M, Basti S et al. NCCN Task Force report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Cancer Netw. 2009; 7(suppl 1): 5-21.
  82. Dueland S, Sauer T, Lund-Johansen F, et al. Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol. 2003; 42: 345–46.
  83. Agero AL, Dusza SW, Benvenuto-Andrade C et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006; 55: 657–670.
  84. Roé E, Muret M, Marcuello E et al. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Derm. 2006; 55: 429–437.
  85. Segaert S, Chiritescu G, Lemmens L et al. Skin toxicities of targeted therapies. Eur J Cancer. 2009; 45 (suppl 1): 295-308.
  86. Lacouture ME, Wu S, Robert C et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13: 1001-11.
  87. Wood L S. Managing the side effects of sorafenib and sunitinib. Commun Oncol 2006; 3: 558–562.
  88. Hammond- Thelin LA. Cutaneous reactions related to systemic immunomodulators and targeted therapeutics. Dermatol Clin. 2008; 26: 121– 159.
  89. Bernhardson B-M, Tishelman C, Rutqvist LE. Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer 2008;16:275– 283.
  90. Zabernigg A, Gamper EM, Giesinger J M.Taste Alterations in Cancer Patients Receiving Chemotherapy: A Neglected Side Effect? The Oncologist 2010;15:913–920. www.TheOncologist.com
  91. Hovan AJ, Williams PM, Stevenson-Moore P et al. A systematic review of dysgeusia induced by cancer therapies. Supportive Cancer Care (2010) 18:1081-1087. 
  92. Wassermann EA. Management of chemotherapy-induced dysgeusia. OncolLink-Abramson Cancer Center of the University of Pennsylvania. http://www.onkolink.org - Last modified August 1, 2012.
  93. Halyard et al (2007) Does zinc sulfate prevent therapy-induced taste alterations in head and neck cancer patients? Results of phase III double-blind, placebo-controlled trial from the North Central Cancer Treatment Group (N01C4). Int J Radiat Oncol Biol Phys 67(5):1318–1322.
  94. Rehwaldt M, Wickman R, Purl S et al. (2009). Self-care strategies to cope with taste changes after chemotherapy. Oncology Nursing Forum, 36, E 47-56. doi: 10.1188/09.ONF.E47-E56.
  95. Hong JH, Omur-Ozbek P, Stanek BT et al. (2009). Taste and odor abnormalities in cancer patients. The Journal of Supportive Oncology, 7, 58-65. Retrieved from http://www.supportiveoncology.net/journal/articles/0702058.pdf
  96. American Institute for Cancer Research. 2010. Nutrition of the cancer patient. Washington, DC. Retrieved from http://www.aicr.org/site/DocServer/Nutrition_of_Patient.pdf‚docID=1567
  97. Bruera E, Schoeller T, MacEachern T: Symptomatic benefit of supplemental oxygen in hypoxemic patients with terminal cancer: the use of the N of 1 randomizedcontrolledtrial. J Pain Symptom Manage 7 (6): 365-8, 1992.
  98. Bruera E, de Stoutz N, Velasco-Leiva A, et al.: Effects of oxygen on dyspnoea in hypoxaemic terminal-cancer patients. Lancet 342 (8862): 13-4, 1993.
  99. Jennings AL, Davies AN, Higgins JP, et al: A systematic review of the use of opioids in the management of dyspnoea. Thorax 57(11):939–944, 2002.
  100. American Thoracic Society: Dyspnea. Mechanisms, assessment, and management: A consensus statement. Am J Respir Crit Care Med 159(1):321–340, 1999.
  101. National Comprehensive Cancer Network: NCCN Practice Guidelines in Oncology–v.1.2006 Palliative Care, 2006.
  102. Campbell ML: Terminal dyspnea and respiratory distress. Crit Care Clin 20(3):403–417, 2004.
  103. Dudgeon DJ: Managing dyspnea and cough. Hematol Oncol Clin North Am 16(3):557–577, 2002.
  104. Ripamonti C: Management of dyspnea in advanced cancer patients. Support Care Cancer 7(4):233–243, 1999.
  105. M. Karthaus. Palliativmedizinische Aspekte: Atemnot. www.onkodin.de. ONKODIN Startseite > Supportive Therapie > Supportivtherapie bei malignen Erkrankungen > 20 Palliativmedizinische Aspekte > Atemnot. Letzte Änderung: 25.01.2006
  106. Kvale PA, Selecky PA, Prakash UB. Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007 Sep;132(3 Suppl):368S-403S.
  107. Karthaus M. Palliativmedizinische Aspekte: Perikarderguss, Pleuraerguss. www. onkodin.de. Letzte Änderung: 25.01.06
  108. Cornelison M, Jabbour E J, Welch M A. Managing Side Effects of TKI Therapy to Optimize Adherence in CML Patients. J Support Oncol 2012; 10:14–24.
  109. Quintás-Cardama A, Cortés J E, Kantarjian H. Practical Management of Toxicities Associated with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia. Clinical Lymphoma & Myeloma 2008; Vol. 8, Suppl. 3: 82-S88
  110. NCCN. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. Version 1.2012. Fort Washington, PA: National Compre- hensive Cancer Network; 2011. 
  111. Saglio G, Kim DW, Issaragrisil S et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362: 2251-2259.
  112. Mauro MJ, Deininger MW. Management of drug toxicities in chronic myeloid leukaemia. Best Pract Res Clin Haematol. 2009; 22: 409-429. 
  113. Quintas-Cardama A, Kantarjian H, O’Brien S et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol. 2007; 25: 3908-3914.
  114. Masiello D, Gorospe G, Yang A. The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib. J Hematol Oncol. 2009; 2: 46. 
  115. Druker BJ, Sawyers CL, Kantarjian H et al: Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
  116. Druker BJ, Talpaz M, Resta D et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037. Ford J, unpublished data.
  117. Deininger MWN, O’Brien SGO, Ford JM et al. Practical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib. J Clin Oncol 2003; 21:1637-1647.
  118. Ebnoether M, Stentoft J, Ford J et al. Cerebral oedema as a possible complication of treatment with imatinib. Lancet 2002; 359: 1751-1752.
  119. Ford J, unpublished data.
  120. Shah-Khan FM , Pinedo D, Shah P. Reversible posterior leukoencephalopathy syndrome and anti-neoplastic agents: a review. Oncol Rev 2007;1:152–161.
  121. Cumurciuc R, Martinez-Almoyna L, Henry C et al. Posterior reversible encephalopathy syndrome during sunitinib therapy. Rev Neurol (Paris) 2008;164:605–607.
  122. Chelis L, Sourtas V, Amarantidis K et al. Reversible posterior leukoencephalopathy syndrome induced by pazopanib. BMC Cancer 2012;12:489.
  123. Chemotherapy-related posterior reversible leukoencephalopathy syndrome. CME Information. CME released 03/05/2009. http:/www.medscape.org/viewarticle/588972
  124. Legriel S, Pico F, Azoulay E. Understanding posterior reversible encephalopathy syndrome. Annual Update In Intensive Care and Emergency Medicine 2011; Band 1. http:/www.springer.com/978-3-642-18080-4
  125. Lee VH, Wijdicks EF, Manno EM et al. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol 2008;65(2):205-210.
  126. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 2007;28(7):1320-1327.
  127. National Cancer Institute (NCI). Sleep disorders (PDQ®), health professional version. Updated August 31, 2010. http://www.cancer.gov/cancertopics/pdq/supportivecare/sleepdisorders/healthprofessional/allpages. Accessed December 14, 2010.
  128. Graci G. Pathogenesis and management of cancer-related insomnia. J Support Oncol. 2005;3:349-359.
  129. National Comprehensive Cancer Network, Inc. 2012: NCCN Guidelines Palliative Care Version 2.2012, 04/23/12. http://www.nccn.org/professionals/physician_gls/pdf/palliative.pdf
  130. Karthaus M. Palliativmedizinische Aspekte: Schlafstörungen. Letzte Änderung: 25.01.2006. http://www.onkodin.de
  131. Page M S, Berger A M, Johnson L B et al. Putting evidence into practice: evidence-based interventions for sleep-wake disturbances. Clin J Oncol Nurs. 2006 Dec;10(6):753-767.
  132. Manage CRC.com - A forum for healthcare practitioners promoting colorectal cancer prevention and managing the care of patients with colorectal cancer. Symptom management. Sleep disorders. Letzter Zugriff am 27.11.12.
  133. Block KI, Gyllenhaal C, Mead MN (2004). Safety and efficacy of herbal sedatives in cancer care. Integrative Cancer Therapies, 3, 128–148.
  134. Link H. Supportivtherapie: Infektionen bei Neurtropenie. http://www.krebsgesellschaft.de/download/ll_o_06.pdf
  135. Link H, Bohme A, Cornely OA et al. Antimicrobial therapy of unexplained fever in neutropenic patients - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003; 82 (Suppl 2): 105–117.
  136. Link H, Buchheidt D, Maschmeyer G et al. Arbeitsgemeinschaft Infektionen in der Hämatologie und Onkologie (AGIHO), Sektion Infektionen in der Hämatologie und Onkologie, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie, Deutschsprachige Mykologische Gesellschaft. (2006) Infektionen bei Neutropenie – Diagnostik und Therapie 2006 – Empfehlungen für die Praxis. http://www.dgho-infektionen.de/agiho/content/e2735/
  137. Link H, Maschmeyer G, Meyer P et al. for the study group of the Paul Ehrlich Society for Chemotherapy (1994) Interventional antimicrobial therapy in febrile neutropenic patients. Ann Hematol 69: 231–243.
  138. Schiel X, Link H, Maschmeyer G et al. A Prospective, Randomized Multicenter Trial of the Empirical Addition of Antifungal Therapy for Febrile Neutropenic Cancer Patients: Results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. Infection 2006; 34: 118–126.
  139. Link H. Prophylaxe und Therapie von Infektionen. www.onkodin.de. Letzte Änderung 25.01.2006.
  140. Sandherr M, Maschmeyer G. Antimikrobielle Therapie bei Patienten mit malignen Erkrankungen. Infektionen stoppen und Komplikationen vermeiden. Im Focus Onkologie (2008) 10: 54-60.
  141. Lipp H-P, Berger B, Enkel S et al. Supportive Therapie bei Tumorerkrankungen - Südwestdeutsches Tumorzentrum, Universitätsklinikum Tübingen - 3. überarbeitete Auflage Januar 2012. http://www.tumorzentrum-tuebingen.de
  142. Maschmeyer G et al. Ann Hematol (Suppl 2) 2003; 82: S118 –S126
  143. Ruhnke M. ASORS-Fortbildung: Invasive Mykosen in der Onkologie. Im Fokus Onkologie (2008) 6: 45-50.
  144. Patterson TF et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79: 250–60.
  145. Böhme A et al. Onkopedia-Leitlinie: Empfehlungen der Deutschen Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO) zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen http://www.dgho-onkopedia.de/de/onkopedia/leitlinien/invasive-pilzinfektionen-therapie
  146. Maschmeyer G in Suttorp N et al. (Hrsg.) Thieme 2004, S. 559– 71.
  147. Klastersky J et al. J Clin Oncol 2000; 18: 3038– 51.
  148. Elting LS, Cooksley C, Chambers M et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapyinduced mucositis. Cancer. 2003; 98: 1531–9.
  149. Peterson DE, Bensadoun RJ, Roila F. Management of oral and gastrointestinal mucositis: ESMO clinical practice guidelines. Ann Oncol. 2010; 21(suppl 5):v261–5.
  150. Rubenstein EB, Peterson DE, Schubert M et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer. 2004; 100(suppl 9):2026–46.
  151. Keefe DM, Schubert MM, Elting LS et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007; 109:820–31.
  152. Bensinger W, Schubert M, Ang KK et al. NCCN task force report: prevention and management of mucositis in cancer care. J Natl Compr Canc Netw. 2008; 6(suppl 1):S1–21.
  153. Hensley ML, Hagerty KL, Kewalramani T et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009; 27:127–45.
  154. Harris DJ, Eilers J, Harriman A, Cashavelly BJ, Maxwell C. Putting Evidence into Practice: Evidence-based interventions for the management of oral mucositis. Clinical Journal of Oncology Nursing. 2008; 12(1):141-152. 
  155. Edward Li, James A. Trovato. New Developments in Management of Oral Mucositis in Patients With Head and Neck Cancer or Receiving Targeted Anticancer Therapies. Am J Health Syst Pharm. 2012;69(12):1031-1037.
  156. Hudes GR, Carducci MA, Choueiri TK et al. NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy. JNCCN 2011;9[Suppl 1]:S1–S29.
  157. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008;13:1084–1096.
  158. Ravaud A. How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. Ann Oncol 2009;20(Suppl 1):i7–12.
  159. Lipp H-P, Berger B, Enkel S et al. Supportive Therapie bei Tumorerkrankungen - Südwestdeutsches Tumorzentrum, Universitätsklinikum Tübingen - 3. überarbeitete Auflage Januar 2012. http://www.tumorzentrum-tuebingen.de 
  160. Le QT, Kim HE, Schneider CJ et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo-controlled study. J Clin Oncol. 2011; 29:2808–14.
  161. Henke M, Alfonsi M, Foa P et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2011; 29:2815–20.
  162. NCCN. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. Version 1.2012. Fort Washington, PA: National Comprehensive Cancer Network; 2011.
  163. Mascha J, Orther P. ASO-Fortbildung: Aktuelle Leitlinien und immer neue Herausforderungen. Im Focus Onkologie 2007; 3: 46-52.
  164. Kreienberg R, Gossmann S, Wickert S et al. Manual onkologische Therapie: Supportive Therapie. Universitätsfrauenklinik Ulm 2009. www.uni-ulm.de/klinik/ufk
  165. Smith TJ, Khatcheressian J, Lymann GH et al. Update of redommendations fort he use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24: 3187-3205.
  166. Ajithkumar TV, Barret A, Hatcher H. Oxford desk reference oncology. Oxford University Press 2011.
  167. Lipp H-P, Berger B, Enkel S et al. Supportive Therapie bei Tumorerkrankungen - 1/2012. http://www.medizin.uni-tuebingen.de/uktmedia/Einrichtungen/Zentren/Tumorzentrum/PDF_Archiv-p-765/Therapieempfehlungen/TLL_Supportive_Therapie.pdf
  168. Continuous Medical Education - Thrombozytopenie. Praxis 2010;99(15):881-892.
  169. Horneber M, Fischer I, Fernando D et al. Tumor-assoziierte Fatigue. Deutsches Arzteplatt, Jg. 109, Heft 9,2. März 2012: 161-172.
  170. Lipp H-P, Berger B, Enkel S et al. Supportive Therapie bei Tumorerkrankungen - Südwestdeutsches Tumorzentrum, Universitätsklinikum Tübingen - 3. überarbeitete Auflage Januar 2012. http://www.tumorzentrum-tuebingen.de
  171. Berger AM, Abernethy AP, Atkinson A et al. Cancer-related fatigue. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines TM) Version 1.2011.
  172. Kuhnt S, Ehrensperger C, Singer S et al. Prädiktoren tumorassoziierter Fatigue. Psychotherapeut 2011;56:216-23.
  173. NCCN Guidelines Version 1.2013. Cancer-Related Fatigue.
  174. Abdominal Pain and Cancer - Managing Side Effects – Chemocare. Accessed 20.11.12. http://chemocare.com/chemotherapy/side-effects/abdominal-pain-and-cancer.aspx 
  175. Jordan K, Bokemeyer C, Langebrake C, Link H. Antiemetische Prophylaxe gemäß MASCC und ASCO Guidelines.
  176. Kris MG, Hesketh PJ, Somerfield MR et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 2006; 24: 2932-2947.
  177. Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 2006; 17: 20-28.
  178. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Antiemesis. Version 1.2013.
  179. Lipp H-P, Berger B, Enkel S et al. Supportive Therapie bei Tumorerkrankungen - 1/2012. http://www. tumorzentrum-tuebingen.de
  180. Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.Ann Oncol. 2010 May;21 Suppl 5:v232-43.
  181. Ryan J. Treatment of chemotherapy-induced nausea in cancer patients. Eur Oncol. 2010; 6(2): 14-16
  182. Maroun JA, Anthony LB, Blais N et al. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol. 2007 February; 14(1): 13–20.
  183. Stein A, Voigt W, Jordan K et al. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol (2010)2(1)51-63.
  184. Lavo B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome—a double-blind placebo controlled study. Scand J Gastroenterol Suppl 1987;130:77–80.
  185. Tijtgat GN, Meuwissen SG, Huibregtse K. Loperamide in the symptomatic control of chronic diarrhoea. Double-blind placebo- controlled study. Ann Clin Res 1975;7:325–30.
  186. Hartmann JT, Bokemeyer C. Therapie oropharyngealer und gastrointestinaler Nebenwirkungen: Diarrhö. http://www.onkodin.de - Letzte Änderung 2006.
  187. H. Link, C. Bokemeyer. Supportivtherapie - Anämie bei Krebs. www.krebsgesellschaft.de/download/ll_o_05.pdf
  188. Link H. Anämie bei Krebs (Teil II) Behandlung der Anämie von Tumorpatienten. Ausgabe 4/2009 von Im Focus Onkologie oder www.im-focus-onkologie. de/fortbildung/fortbildungsreihe_supportivtherapie. php und www.onkosupport.de.
  189. Bokemeyer C, Aapro MS, Courdi A et al. (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer. 43:258 – 270
  190. Schrijvers D, De Samblanx H, Roila F. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Annals of Oncology 21 (Supplement 5): 244–247, 2010.
  191. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Cancer- and Chemotherapy- Induced Anemia. Version 1.2014, 06/05/13. http://www.nccn.org/professionals/physician_gls/pdf/anemia.pdf
  192. Gibson R J, Keefe D M K. Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Published online: 8 April 2006. http://link.springer.com/article/10.1007/s00520-006-0040-y/fulltext.html
  193. Woolery M, Bisanz A, Lyons H F et al. Putting evidence into practice: evidence-based interventions for the prevention and management of constipation in patients with cancer. Clin J Oncol Nurs. 2008 Apr;12(2):317-37.
  194. Kreienberg R, Gossmann S, Wickert S et al. Manual onkologische Therapie 2009. http://www.uniklinik-ulm.de/fileadmin/Kliniken/Frauenklinik/Download/Onkomanual-UFK-Ulm-2009.pdf
  195. National Comprehensive Cancer Network (NCCN): Clinical practice guidelines in oncology: Palliative care. Version 2.2012
  196. Avila J G. Pharmacologic treatment of constipation in cancer patients. (2004) Cancer Control, 11(3, Suppl), 10–18.
  197. McNicol E, Horowicz-Mehler N, Fisk RA et al. (2003). Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review. Journal of Pain, 4(5), 231–256.
  198. Miaskowski C, Cleary J, Burney R et al. (2005). Guideline for the management of cancer pain in adults and children. Glenview, IL: American Pain Society.
  199. Klaschik E, Nauck F, Ostgathe C (2003). Constipation - Modern laxative therapy. Supportive Care in Cancer, 11(11), 679–685.
  200. Hartmann JT, Bokemeyer C. Therapie oropharyngealer und gastrointestinaler Nebenwirkungen: Obstipation. http://www.onkodin.de - Letzte Änderung 2006.
  201. Adams L, Cunningham R, Shepard N, Caruso RA, Norling MJ, Belansky H (2008). Putting Evidence Into Practice: Evidence-based interventions to prevent and manage anorexia. Clinical Journal of Oncology Nursing, 13(1), 95-102.
  202. Adams L, Shepard N, Caruso RA et al. Putting evidence into practice: evidence-based interventions to prevent and manage of anorexia. Clin J Oncol Nurs. 2009 Feb;13(1):95-102. 
  203. DeWys WD, Begg C, Lavin PT, Band PR, Bennett JM, Bertino JR.?Prognostic effect of weight loss prior to chemotherapy in cancer patients.?Am J Med 1980;69:491-497.
  204. Vestweber K-H, Paul C. Tumorerkrankungen und Ernährung: Anorexie. www.onkodin.de Letzte Änderung 2006.
  205. Belloni B et al. Cuteneous drug eruptions associated with the use of new oncological drugs. Chem Immunol Allergy 2012:191-202.
  206. Wollenberg A, CME-Fortbildung: Management kutaner Nebenwirkungen von EGFR-Inhibitoren. Journal Onkologie online, Ausgabe 04-10.
  207. Sun V. Management of treatment-induced dermatologic toxicities in palliative care. Journal of Hospice & Palliative Nursing 2012; Number 1,Vol. 14: 80-85.
  208. Gutzmer R, Wollenberg A, Ururel S et al. Kutane Nebenwirkungen von neuen medikamentösen Tumortherapien: Klinik und Management Cutaneous Side Effects of New Antitumor Drugs: Clinical Features and Management
  209. Belloni B, Schönewolf M, Rozati S et al. Cuteneous drug eruptions associated with the use of new oncological drugs. Chem Immunol Allergy 2012.:191-202.
  210. Gutzmer R, Wollenberg A, Ururel S et al. Kutane Nebenwirkungen von neuen medikamentösen Tumortherapien: Klinik und Management Cutaneous Side Effects of New Antitumor Drugs: Clinical Features and Management Dtsch Arztebl Int 2012; 109(8): 133-40;
  211. Wollenberg A, CME-Fortbildung: Management kutaner Nebenwirkungen von EGFR-Inhibitoren. Journal Onkologie online, Ausgabe 04-10. 
  212. Gutzmer R, Becker JC, Enk A, et al.: Management kutaner Nebenwirkungen von FGFR-Inhibitoren: Empfehlungen eines deutschen Expertengremiums für den primär behandelnden Arzt. J Dtsch Dermatol Ges 2011; 9: 195–203.
  213. Sun V. Management of treatment-induced dermatologic Toxicities in palliative care. Journal of Hospice & Palliative Nursing. Jan 2012, Vol. 14, No. 1: 80-85.
  214. Fakih M, Vincent M: Adverse event associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol 2010;17(suppl 1): S18-S30.
  215. Burtness B, Anadkat M, Basti S, et al. NCCN Task Force report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Cancer Netw. 2009;7(suppl 1):S5-S21.
  216. Wu PA, Balagula Y, Lacouture ME, Anadkat MJ. Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors. Curr Opin Oncol. 2011;23(4):343-351.
  217. Eames T, Kroth J, Flaig MJ, Ruzicka T, Wollenberg A: Perifollicular xanthomas associated with epidermal growth factor receptor inhibitor therapy. Acta Derm Venereol 2010; 90: 202–3.
  218. Gutzmer R, Wollenberg A, Ururel S et al. Kutane Nebenwirkungen von neuen medikamentösen Tumortherapien: Klinik und Management Cutaneous Side Effects of New Antitumor Drugs: Clinical Features and Management Dtsch Arztebl Int 2012; 109(8): 133-40;
  219. Belloni B et al. Cuteneous drug eruptions associated with the use of new oncological drugs. Chem Immunol Allergy 2012.:191-202.
  220. Wollenberg A, CME-Fortbildung: Management kutaner Nebenwirkungen von EGFR-Inhibitoren. Journal Onkologie online, Ausgabe 04-10.
  221. Sun V. Management of treatment-induced dermatologic toxicities in palliative care. Journal of Hospice & Palliative Nursing 2012; Number 1,Vol. 14: 80-85.
  222. Potthoff, K Hassel J, Wollenberg A et al. Terapie und Prophylaxe EGRF-Inhibitor-induzierter Hautreaktionen. Arzneimitteltherapie 2010; 28:191-8.
  223. Lacouture M, Anadkat M, Bensadoun R-J, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitorassociated dermatologic toxicities. Support Care Cancer. 2011; 19(8):1079-1095.
  224. Balagula Y, Garbe C, Myskowski PL, et al. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol. 2011;50(2): 129-146.
  225. Gutzmer R, Wollenberg A, Ururel S et al. Kutane Nebenwirkungen von neuen medikamentösen Tumortherapien: Klinik und Management Dtsch Arztebl Int 2012; 109(8): 133-40.
  226. Robert C, Mateus C, Spatz A, Wechsler J, Escudier B: Dermatologic symptoms associated with the multikinase inhibitor sorafenib. J Am Acad Dermatol 2009;60:299– 305.
  227. Anderson R, Jatoi A, Robert C, Wood LS, Keating KN, Lacouture ME: Search for evidence- based approaches for the prevention and palliation of handfoot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs). Oncologist 2009;14:291– 302.
  228. Belloni B, Schönewolf M, Rozati S et al. Cuteneous drug eruptions associated with the use of new oncological drugs. Chem Immunol Allergy 2012:191-202.
  229. Degen A, Alter M, Schenck F, et al.: Das Hand-Fuß-Syndrom als Nebenwirkung der medikamentösen Tumortherapie – Klassifikation und Management. J Dtsch Dermatol Ges 2010; 8: 652–61.
  230. Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008;13:1001?11.
  231. Autier J, Escudier B, Wechsler J, Spatz A, Robert C: Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008;144:886– 892.
  232. Druker BJ, Talpaz M, Resta D et al: Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037. Ford J, unpublished data.
  233. Ford J, unpublished data.
  234. N.Scuola, Kreuter A , Altmeyer P et al. Ausgeprägtes periorbitales Ödem und Behandlung mit Imatinib (Glivec ®). Akt Dermatol 2010; 36(4): 133-135.
  235. Esmaeli B, Prieto VG, Butler CE, et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer 2002; 95(4): 881–887.
  236. Frauenfelder FW, Solomon J, Druker BJ et al. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther. 2003 Aug; 19(4): 371-5.
  237. McClelland CM, Harocopoc G, Custer PL. Periorbital edema secondary to imatinib mesylate. Clinical Ophtalmology 2010; 4: 427-431.
  238. Ramar K, Potti A, Mehdi SA. Uncommon syndromes and treatment manifestations of malignancy: Case 4. Periorbital edema and imatinib mesylate therapy for chronic myelogenous leukemia. J Clin Oncol 2003; 21: 172-173.
  239. Druker BJ, Sawyers CL, Capdeville R et al. Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program) 2001: 87-112.
  240. NCCN. National Comprehensive Cancer Network: Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. Version 1.2012. 
  241. Esmaeli B, Diba R, Ahmadi MA et al. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). Eye (2004) 18, 760-762.
  242. Corinelison M, Jabbour EJ, Welch MA. Managing side effects of tyrosine kinase inhibitor therapy to optimize adherence in patients with chronic myeloid leukemia: the role for he midlevel practiotioner. J Support Oncol 2012; 10: 14-24.
  243. Hazin R, Abuzetun JY, Daoud YJ, Abu-Khalaf MM. Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients. Curr Opin Ophthalmol. 2009; 20: 308-317.
  244. Schmid KE, Kornek GV, Scheithauer W, Binder, S. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol. 2009; 20: 308-317. 
  245. Parul S, Abhishek S. Ocular adverse effects of anti-cancer chemotherapy and targeted therapy. Journal of Cancer Therapeutics and Research 2012 , http://www.hoajonline.com/journals/pdf/2049-7962-1-5.pdf
  246. Omoti AE, Omoti CE. Ocular toxicity of systemic anticancer chemotherapy. Pharm Pract. 2006; 4: 55-59.
  247. Treatment Side Effects: Mood Swings. Last modified on March 27, 2013. http://www.breastcancer.org/treatment/side_effects/mood_swings
  248. National Cancer Institute Fact Sheet. Hormone Therapy for Breast Cancer. http://www.cancer.gov/cancertopics/factsheet/Therapy/hormone-therapy-breast. Accessed June 2013
  249. American Cancer Society. Breast Cancer. http://www.cancer.org/acs/groups/cid/documents/webcontent/003090-pdf.pdf. Accessed June 2013
  250. Von Ah D, Kang DH. Correlates of mood disturbance in women with breast cancer: patterns over time. J Adv Nurs. 2008 Mar;61(6):676-89. doi: 10.1111/j.1365-2648.2007.04563.x.
  251. Carpenter JS, Andrykowski MA. Menopausal symptoms in breast cancer survivors. Oncol Nurs Forum 1999;26:1311–1317. 
  252. Carpenter JS, JohnsonD, Wagner L etal. Hotflashes and related outcomes in breast cancer survivors and matched comparison women. Oncol Nurs Forum 2002;29:E16–E25.
  253. Ganz PA, Coscarelli A, Fred C et al. Breast cancer survivors: psychosocial concerns and quality of life. Breast Cancer Res Treat 1996;38:183–199.
  254. Carpenter JS, Elam JL, Ridner SH etal. Sleep, fatigue, and depressive symptoms in breast cancer survivors and matched healthy women experiencing hot flashes. Oncol Nurs Forum 2004;31:591–598.
  255. Knobf MT. The menopausal symptom experience in young mid-life women with breast cancer. Cancer Nurs 2001;24:201–210.
  256. Ochayon L, Zelker R, Kaduri L, et al. Relationship between severity of symptoms and quality of life in patients with breast cancer receiving adjuvant hormonal therapy. Oncol Nurs Forum. 2010 Sep;37(5):E349-58. 
  257. Listing M, Reisshauer A, Krohn M, et al. Massage therapy reduces physical discomfort and improves mood disturbances in women with breast cancer. Psychooncology. 2009 Dec;18(12):1290-9. 
  258. Goldman JM. Marin D. Is imatinib still an acceptable fist-line treatment for CML in chronic phase? Oncology. Vol 26 October 2012. www.cancernetwork.com
  259. Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol. 2003 Apr 15;21(8):1637-47.
  260. Younus J, Kligman L. Management of aromatase inhibitor-induced arthralgia. Curr Oncol. 2010 Feb;17(1):87-90.
  261. Sestak I, Cuzick J, Sapunar F, et al., ATAC Trialists’ Group: Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 2008, 9:866-872.
  262. Burstein HJ: Aromatase inhibitor-associated arthralgia syndrome. Breast 2007, 16:223-234.
  263. Presant CA, Bosserman L, Young T, et al. Aromatase inhibitor-associated arthralgia and/ or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer 2007, 7:775-778.
  264. Henry NL, Giles JT, Ang D, et al. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 2008, 111:365-372.
  265. Donnellan PP, Douglas SL, Cameron DA, et al. Aromatase inhibitors and arthralgia. J Clin Oncol 2001, 19:2767.
  266. Gaillard S and Stearns V. Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Research 2011, 13:205-211.
  267. Niravath P. Aromatase inhibitor-induced arthralgia: a review. Ann Oncol. 2013 Jun;24(6):1443-9. 
  268. Cecil R, Archer B. Arthritis of Menopause. JAMA 1925; 84: 75–79.
  269. Le Bail J, Liagre B, Vergne P, et al. Aromatase in synovial cells from postmenopausal women. Steroids 2001, 66:749-757. 
  270. Sasano H, Uzuki M, Sawai T, et al. Aromatase in human bone tissue. J Bone Miner Res 1997, 12:1416-1423. 
  271. Buzdar AU, on behalf of the ATAC Trialists’ Group. Clinical features of joint symptoms observed in the Arimidex, Tamoxifen,?Alone or in Combination (ATAC) trial [abstract 551]. Proc Am Soc?Clin Oncol 2006;24. 
  272. Buzdar A, Howell A, Cuzick J, on behalf of the ATAC Trialists’?Group. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast can-?cer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7:633–43. 
  273. Mao JJ, Stricker C, Bruner D, et al. Patterns and risk factors associated with aromatase inhibitor- related arthralgia among breast cancer survivors. Cancer 2009, 115:3631-3639.
  274. Garland CF, Gorham ED, Mohr SB, et al. Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol 2007;103:708–11.
  275. Bocca C, Bozzo F, Bassignana A et al. Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines. Mol Cell Biochem 2011; 350: 59–70.
  276. Arzneimittelkompendium der Schweiz
  277. NCCN. National Comprehensive Cancer Network: NCCN Guidelines Version 4.2013. Chronic Myelogenous Leukemia.
  278. Eisen T, Sternberg C, Robert C et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. J Natl Cancer Inst. 2012 Apr 18;104(8):638.
  279. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006-2013. 
  280. Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 2013;63:249–279.
  281. Vergès B, Walter T, Cariou B. Effects of anti-cancer targeted therapies on lipid and glucose metabolism. Eur J Endocrinol. 2014;170:2; R43–R55.
  282. Park SM, Lim MK, Shin SA, et al: Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol 24:5017-5024, 2006.
  283. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:837-853, 1998.
  284. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes melli- tus: The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977-986, 1993.
  285. American Diabetes Association: Standards of medical care in diabetes. Diabetes Care 34: S11–S61, 2011 (suppl 1).
  286. Busaidy NL, Farook A, Dowlati A, et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 30:2919-2928.
  287. Deininger MWN, O’Brien SGO, Ford JM et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003; 21:1637-1647.
  288. Aduwa E, Szydlo R, Marin D, et al. Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy. Blood. 2012;120(25):5087-5088. 
  289. Rock DL, Flatt SW, Newman V et al. Factors associated with weight gain in women after diagnosis of breast cancer. Women’s healthy eating and living study group. Am Diet Assoc. 1999; 99: 1212-21.
  290. Irwin ML, Crumley D, McTiernan A et al. Physical activity levels before and after diagnosis of breast carcinoma: the Health, Eating, Activity, and Lifestyle (HEAL) study. Cancer 2003, 97:1746-57.
  291. McInnes JA, Knobf MT.?Weight gain and quality of life in women treated with adjuvant chemotherapy for early-stage breast cancer. Oncol Nurs Forum. 2001 May; 28(4): 675-84.
  292. Malinovsky KM, Cameron D, Douglas S et al. Breast cancer patients’ experiences on endocrine therapy: monitoring with a checklist for patients on endocrine therapy (C-PET). The Breast (2004) 13: 363-368.
  293.  Szfranski M. Weight gain during cancer treatment. Juli 05, 2012. http://www.cancer.org/cancer/news/expertvoices/post/2012/07/05/weight-gain-during-cancer-treatment.aspx
  294. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6:465- 477.
  295. Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst. 2011 Nov 2;103(21):1572-87. 
  296. Kappers MH, van Esch JH, Smedts FM, et al. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression. J Clin Endocrinol Metab. 2011;96:3087-3094. 
  297. Abdulrahman RM, Verloop H, Hoftijzer H, et al. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab. 2011;95: 3758-3762. 
  298. Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin. 2013 Jul-Aug;63(4):249-79.
  299. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist. 2007; 12(suppl 1):4–10. 
  300. Thomas J. Cancer-related constipation. Curr Oncol Rep. 2007;9(4): 278–284. 
  301. Eisen T, Sternberg CN, Robert C, et al . Targeted Therapies for Renal Cell Carcinoma: Review of Adverse Event Management Strategies. J Natl Cancer Inst. 2012;104(2):93-113.
  302. Hennessey JV, Scherger JE (2007) Evaluating and treating the patient with hypothyroid disease. J Fam Pract 56:S31–S39.
  303. Hudes GR, Carducci MA, Choueiri TK, et al. NCCN Task Force Report: Optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. JNCCN 2011; 9: S1-S29.
  304. Wilkes G. Clinical Use of Antiangiogenic Agents: Dosing, Side Effects, and Management Oncology 2007. Vol 21, No 14. Nursehttp://www.cancernetwork.com/display/article/10165/59068#
  305. Wolter P, Stefan C, Decallonne B, et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer. 2008;99(3):448–454.
  306. Altmeyer P, Hoffmann K. Basiswissen Dermatologie: eine vorlesungsorientierte Darstellung. W3l GmbH, 2006 – 497 Seiten.
  307. Neumann NJ, Lehmann P. Photodermatosen: Ein Leitfaden zur Diagnostik.
  308. Reinhardt D. Therapie Der Krankheiten Im Kindes- und Jugendalter. Springer DE?, 2004 - 2104 Seite??n.?
  309. Proksch E et al. (2007) Rationale Behandlung von Patienten mit Verbrennungen 1.Grades. Hautarzt 58: 604-610.
  310. Hinshaw DB, Carnahan JM, Johnson DL. Depression, anxiety, and asthenia in advanced illness. Jam Coll Surg. 2002; 195: 271-277.
  311. Saguil A. Evaluation of he patient with muscle weakness. Am Fam Physician. 2005 Apr 1;71(7):1327-1336. 
  312. Dalakas MC. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry. 2009; 80: 832– 838. 
  313. J.-S. Le Quintrec, J.-L. Le Quintrec. Drug-induced myopathies. Baillieres Clin Rheumatol. 1991 Apr; 5(1): 21-38.
  314. Valiyil R and Christopher-Stine L. Drug-related myopathies of which the clinician should be aware. Curr Rheumatol Rep. 2010 June; 12(3): 213-220.
  315. Evans M, Rees A: Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf. 2002; 25: 649-663.
  316. Deangelo DJ. Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy. Blood Cancer J. 2012 Oct 19;2:e95. 
  317. Howell A, Cuzick J, Baum M et al. results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 23: 738s.
  318. Mortimer J. Long-term consequences oft he Aromtatase Inhibitors. www. medscape.or. Posted 11/16/2005.
  319. Deangelo DJ. Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy. Blood Cancer J. 2012 Oct 19;2:e95. 
  320. Caocci G, Maioli MA, Atzeni S, et al. Absence of histological myopathy in chronic myeloid leukemia patients complaining of muscle spasms and myalgia during treatment with nilotinib. Leuk Res. 2012 Sep;36(9):e206-8.
  321. Mortimer J. Long-term consequences oft he Aromtatase Inhibitors. www. medscape.org. Posted 11/16/2005.
  322. Monderer RS, Wu WP, Thorpy MJ: Nocturnal leg cramps. Curr Neurol Neurosci Rep 2010; 10: 53–59.
  323. Miller TM, Layzer RB: Muscle cramps. Muscle Nerve 2005; 32: 431–442. 
  324. Reichel G: Wadenkrämpfe (Krampi). Differentialdiagnose und Therapie. Psychoneuro 2007; 33: 462–465.
  325. Mueller EA, Kirch W. Muskelkrämpfe – was tun? Arzneiverordnung in der Praxis. Band 37, Ausgabe 3, Mai 2010.
  326. Wille H. Muskelkrämpfe als unerwünschte Arzneimittelwirkung. Arzneiverordnung in der Praxis. Band 40,Ausgabe 3, Mai 2013. 
  327. Butler JV, Mulkerrin EC, O'Keeffe ST. Nocturnal leg cramps in older people. Postgrad Med J 2002; 78: 596–598. 
  328. Hallegraeff JM, van der Schans CP, de RR, de Greef MH: Stretching before sleep reduces the frequency and severity of nocturnal leg cramps in older adults: a randomised trial. J Physiother 2012; 58: 17–22.
  329. Deininger MW, O’Brien SG, Ford JM et al. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637-1647. 
  330. Said M: Wadenkrämpfe: Behandlung und Prävention. Pharma-Kritik 2002; 24: 5–6.
  331. Lindemuth R: Crampi/Muskelkrampf. In: Diener HC, Putzki N (Hrsg.): Leitlinien für die Diagnostik und Therapie in der Neurologie. 4. Aufl., Stuttgart: Georg Thieme Verlag, 2008; 654–657.
  332. NCCN Guidelines Version 3.2014 Chronic Myelogenous Leukemia. www.nccn.org 
  333. Young G: Leg cramps. Clin Evid (Online) 2009; 03: 1113.

Red Flags

  1. Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. 
  2. Kedar RP, Bourne TH, Powles TJ, Collins WP, Ashley SE, Cosgrove DO, Campbell S. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 1994 May 28;343(8909):1318-21.
  3. Braithwaite RS, Chlebowski RT, Lau J, George S, Hess R, Col NF. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med. 2003 Nov;18(11):937-47.
  4. Diesing D, Friedrich M, von Otte S. Nebenwirkungen der endokrinen Therapie beim Mammakarzinom. Gynäkologische Endokrinologie 2005 (3):91-96.
  5. Vandewiele B, Vandecasteele SJ, Vanwalleghem L, De Vriese AS. Diffuse alveolar hemorrhage induced by everolimus. Chest. 2010 Feb;137(2):456-9.
  6. Aparicio G, Calvo MB, Medina V, Fernandez O, Jimenez P, Lema M, et al. Comprehensive lung injury pathology induced by mTOR inhibitors. Clin Transl Oncol. 2009 Aug;11(8):499-510.
  7. Otton J, Hayward CS, Keogh AM, Glanville AR, Macdonald PS. Everolimus-associated pneumonitis in 3 heart transplant recipients. J Heart Lung Transplant. 2009 Jan;28(1):104-6.
  8. Rodriguez-Moreno A, Ridao N, Garcia-Ledesma P, Calvo N, Perez-Flores I, Marques M, et al. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center. Transplant Proc. 2009 Jul-Aug;41(6):2163-5.
  9. Exposito V, Vasquez de Prada JA, Gomez-Roman JJ, Gonzalez-Vilchez F, Llano-Cardenal M, Garcia-Camarero T, et al. Everolimus-related pulmonary toxicity in heart transplant recipients. Journal of Heart and Lung Transplantation. 2008;27(7):797-800.